Drug intelligence / Profile preview

MT101-5

Development stage: Phase 2
Lead developer: Mthera Pharma
Administration: Oral

Overview

MT101-5 is an investigational oral standardized herbal medicine developed by Mthera Pharma for early Parkinson's disease. It comprises ethanolic extracts of Genkwae Flos, Clematidis Radix, and Gastrodiae Rhizoma. Preclinical studies indicate that diterpenoid constituents derived from Genkwae Flos activate nuclear receptor related 1 protein and the proteasome, suppressing alpha-synuclein fibril formation and promoting alpha-synuclein clearance; neuroprotective activity has been reported in Parkinson's disease mouse models. MT101-5 completed a Phase 1 healthy-volunteer study and is being evaluated in a randomized Phase 2a trial in early Parkinson's disease. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0753332226001265))

Targets

26S proteasomeHSP60 (60 kDa heat shock protein, mitochondrial)SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on MT101-5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT101-5.

Explore the full profile